Fatty acid-binding protein-3 and renal function decline in patients with chronic coronary syndrome.
chronic coronary syndrome
coronary artery disease
estimated glomerular filtration rate
fatty acid-binding protein 3
renal function
Journal
Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
revised:
17
12
2023
received:
08
09
2023
accepted:
20
12
2023
medline:
25
1
2024
pubmed:
25
1
2024
entrez:
25
1
2024
Statut:
ppublish
Résumé
Renal dysfunction is common in patients with coronary artery disease. Due to the shared vascular pathogenesis between the two conditions, novel biomarkers such as the fatty acid-binding protein-3 (FABP-3) have been proposed for diagnosis and prognosis prediction. This multicentre prospective cohort study investigates the association between FABP-3 and renal dysfunction. We hypothesized that higher FABP-3 levels are correlated to worse renal outcome. Patients with chronic coronary syndrome were classified into three groups based on the initial serum FABP-3 levels. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to estimate the patient's renal function. Renal events were defined as >25% and >50% decline in estimated glomerular filtration rate (eGFR). Cox multivariable regression was employed to delineate the correlation between FABP-3 and renal dysfunction. A total of 1606 subjects were included. During a mean follow-up of 35.9 months, there were 239 patients with eGFR >25% reduction and 60 patients with >50% reduction. In the Kaplan-Meier survival curve and log-rank test, increased levels of FABP-3 were significantly correlated with eGFR >25% reduction (p < .001) and >50% reduction (p < .001). Multivariate Cox regression model revealed that subjects with higher FABP-3 exhibited a greater risk of eGFR >25% reduction (Group 2: hazard ratio [HR] = 2.328, 95% confidence interval [CI] = 1.521-3.562, p < .001; Group 3: HR = 3.054, 95% CI = 1.952-4.776, p < .001) and >50% reduction (Group 3: HR = 4.838, 95% CI = 1.722-13.591, p = .003). Serum FABP-3 may serve as a novel biomarker to predict eGFR decline in patients with chronic coronary syndrome.
Sections du résumé
BACKGROUND
BACKGROUND
Renal dysfunction is common in patients with coronary artery disease. Due to the shared vascular pathogenesis between the two conditions, novel biomarkers such as the fatty acid-binding protein-3 (FABP-3) have been proposed for diagnosis and prognosis prediction. This multicentre prospective cohort study investigates the association between FABP-3 and renal dysfunction.
HYPOTHESIS
OBJECTIVE
We hypothesized that higher FABP-3 levels are correlated to worse renal outcome.
METHODS
METHODS
Patients with chronic coronary syndrome were classified into three groups based on the initial serum FABP-3 levels. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to estimate the patient's renal function. Renal events were defined as >25% and >50% decline in estimated glomerular filtration rate (eGFR). Cox multivariable regression was employed to delineate the correlation between FABP-3 and renal dysfunction.
RESULTS
RESULTS
A total of 1606 subjects were included. During a mean follow-up of 35.9 months, there were 239 patients with eGFR >25% reduction and 60 patients with >50% reduction. In the Kaplan-Meier survival curve and log-rank test, increased levels of FABP-3 were significantly correlated with eGFR >25% reduction (p < .001) and >50% reduction (p < .001). Multivariate Cox regression model revealed that subjects with higher FABP-3 exhibited a greater risk of eGFR >25% reduction (Group 2: hazard ratio [HR] = 2.328, 95% confidence interval [CI] = 1.521-3.562, p < .001; Group 3: HR = 3.054, 95% CI = 1.952-4.776, p < .001) and >50% reduction (Group 3: HR = 4.838, 95% CI = 1.722-13.591, p = .003).
CONCLUSIONS
CONCLUSIONS
Serum FABP-3 may serve as a novel biomarker to predict eGFR decline in patients with chronic coronary syndrome.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24210Subventions
Organisme : National Science and Technology Council
ID : NSTC111-2314-B-A49A-509-MY3
Organisme : Academia Sinica
ID : BM10501010039
Organisme : Taipei Veterans General Hospital
ID : V111D63-002-MY2-2
Organisme : Taipei Veterans General Hospital
ID : V112C-062
Organisme : Taipei Veterans General Hospital
ID : V113C-032
Organisme : Taipei Veterans General Hospital
ID : V113EA-012
Organisme : Taipei Veterans General Hospital
ID : VGHUST112-G7-1-2
Informations de copyright
© 2024 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.
Références
Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. The Lancet. 2013;382(9887):158-169.
Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089-2100.
McCullough KP, Morgenstern H, Saran R, Herman WH, Robinson BM. Projecting ESRD incidence and prevalence in the United States through 2030. J Am Soc Nephrol. 2019;30(1):127-135.
Thomas B, Matsushita K, Abate KH, et al. Global cardiovascular and renal outcomes of reduced GFR. J Am Soc Nephrol. 2017;28(7):2167-2179.
Levin A, Stevens PE. Early detection of CKD: the benefits, limitations and effects on prognosis. Nat Rev Nephrol. 2011;7(8):446-457.
Chen S, Tseng CH. Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. Rev Diabet Stud. 2013;10(2-3):88-100.
Hotamisligil GS, Bernlohr DA. Metabolic functions of FABPs- mechanisms and therapeutic implications. Nat Rev Endocrinol. 2015;11(10):592-605.
Liao B, Yang S, Geng L, et al. Development of a therapeutic monoclonal antibody against circulating adipocyte fatty acid binding protein to treat ischaemic stroke. Br J Pharmacol. 2023:1-18. doi:10.1111/bph.16282
Otaki Y, Watanabe T, Kubota I. Heart-type fatty acid-binding protein in cardiovascular disease: a systemic review. Clin Chim Acta. 2017;474:44-53.
Jochmans I, Lerut E, van Pelt J, Monbaliu D, Pirenne J. Circulating AST, H-FABP, and NGAL are early and accurate biomarkers of graft injury and dysfunction in a preclinical model of kidney transplantation. Ann Surg. 2011;254(5):784-792.
Nauta FL, Boertien WE, Bakker SJL, et al. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care. 2011;34(4):975-981.
Tekce H, Tekce B, Aktas G, Alcelik A, Sengul E. Serum omentin-1 levels in diabetic and nondiabetic patients with chronic kidney disease. Exp Clin Endocrinol Diabetes. 2014;122(8):451-456.
Kocak MZ, Aktas G, Atak BM, et al. Is neuregulin-4 a predictive marker of microvascular complications in type 2 diabetes mellitus? Eur J Clin Invest. 2020;50(3):e13206.
Kocak MZ, Aktas G, Duman TT, Atak BM, Savli H. Is uric acid elevation a random finding or a causative agent of diabetic nephropathy? Rev Assoc Med Bras. 2019;65(9):1155-1160.
Kin Tekce B, Tekce H, Aktas G, Sit M. Evaluation of the urinary kidney injury molecule-1 levels in patients with diabetic nephropathy. Clin Invest Med. 2014;37(6):377.
Aktas G. Association between the prognostic nutritional index and chronic microvascular complications in patients with type 2 diabetes mellitus. J Clin Med. 2023;12(18):5952.
Taslamacioglu Duman T, Ozkul FN, Balci B. Could systemic inflammatory index predict diabetic kidney injury in type 2 diabetes mellitus? Diagnostics. 2023;13(12):2063.
Aktas G, Yilmaz S, Kantarci DB, et al. Is serum uric acid-to-HDL cholesterol ratio elevation associated with diabetic kidney injury? Postgrad Med. 2023;135(5):519-523.
Bilgin S, Kurtkulagi O, Atak Tel BM, et al. Does C-reactive protein to serum albumin ratio correlate with diabetic nephropathy in patients with type 2 diabetes mellitus? The CARE TIME study. Primary Care Diabetes. 2021;15(6):1071-1074.
Yu TH, Hsuan CF, Wu CC, et al. Association of plasma fatty acid-binding protein 3 with estimated glomerular filtration rate in patients with type 2 diabetes mellitus. Int J Med Sci. 2022;19(1):82-88.
Schaub JA, Garg AX, Coca SG, et al. Perioperative heart-type fatty acid binding protein is associated with acute kidney injury after cardiac surgery. Kidney Int. 2015;88(3):576-583.
Leu HB, Yin WH, Tseng WK, et al. Identification of new biosignatures for clinical outcomes in stable coronary artery disease-the study protocol and initial observations of a prospective follow-up study in Taiwan. BMC Cardiovasc Disord. 2017;17(1):42.
Tsai WC, Wu HY, Peng YS, et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med. 2017;177(6):792-799.
Kao TW, Huang CC, Chen JW. Optimal blood pressure for the prevention of hypertensive nephropathy in nondiabetic hypertensive patients in Taiwan. J Clin Hypertens. 2020;22(8):1425-1433.
Hung YH, Huang CC, Lin LY, Chen JW. Uric acid and impairment of renal function in non-diabetic hypertensive patients. Front Med. 2021;8:746886.
Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247-254.
Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008;7(6):489-503.
Ishimura S, Furuhashi M, Watanabe Y, et al. Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS One. 2013;8(11):e81318.
Feng Y, Guo F, Xia Z, et al. Inhibition of fatty acid-binding protein 4 attenuated kidney fibrosis by mediating macrophage-to-myofibroblast transition. Front Immunol. 2020;11:566535.
Huang R, Shi M, Guo F, et al. Pharmacological inhibition of fatty acid-binding protein 4 (FABP4) protects against rhabdomyolysis-induced acute kidney injury. Front Pharmacol. 2018;9:917.
Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58(5):295-300.